Wedbush Brokers Decrease Earnings Estimates for BCRX

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Stock analysts at Wedbush dropped their FY2025 earnings per share estimates for shares of BioCryst Pharmaceuticals in a research note issued on Wednesday, April 16th. Wedbush analyst L. Chico now forecasts that the biotechnology company will post earnings of $0.03 per share for the year, down from their previous estimate of $0.04. Wedbush has a “Outperform” rating and a $15.00 price objective on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals’ Q4 2025 earnings at $0.10 EPS, Q1 2026 earnings at $0.02 EPS, Q2 2026 earnings at $0.07 EPS, Q4 2026 earnings at $0.14 EPS, FY2026 earnings at $0.32 EPS, FY2027 earnings at $0.66 EPS and FY2028 earnings at $0.84 EPS.

Several other equities analysts have also issued reports on the stock. Needham & Company LLC restated a “buy” rating and issued a $15.00 target price on shares of BioCryst Pharmaceuticals in a report on Thursday, April 10th. Evercore ISI boosted their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. JMP Securities reissued a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $11.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday, April 11th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $15.57.

BioCryst Pharmaceuticals Stock Performance

NASDAQ:BCRX opened at $7.40 on Thursday. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $9.50. The firm’s fifty day moving average is $7.85 and its 200-day moving average is $7.73. The firm has a market cap of $1.55 billion, a P/E ratio of -12.13 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. During the same quarter in the previous year, the firm earned $0.28 EPS. BioCryst Pharmaceuticals’s revenue was up 40.8% compared to the same quarter last year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of BioCryst Pharmaceuticals by 7.8% in the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock worth $164,616,000 after purchasing an additional 1,583,826 shares in the last quarter. Eversept Partners LP raised its holdings in BioCryst Pharmaceuticals by 269.9% during the fourth quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company’s stock worth $14,892,000 after buying an additional 1,444,907 shares during the last quarter. Hillsdale Investment Management Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 65,213.3% in the fourth quarter. Hillsdale Investment Management Inc. now owns 542,100 shares of the biotechnology company’s stock valued at $4,077,000 after buying an additional 541,270 shares in the last quarter. Balyasny Asset Management L.P. acquired a new position in shares of BioCryst Pharmaceuticals during the fourth quarter valued at about $3,983,000. Finally, Norges Bank bought a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $3,947,000. Institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.